TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20956803

Group type: EXPERIMENTAL
Intervention: Bortezomib-adapted subclones of MCL cell lines JEKO and HBL2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib-adapted subclones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of IRF4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasmacytic differentiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrinsically bortezomib-resistant MCL cell lines and primary tumor cells
Number of subjects: 0
Study: 20958972

Group type: EXPERIMENTAL
Intervention: Hand-held fan (HHF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wristband
Number of subjects: 70
Study: 20958975

Group type: EXPERIMENTAL
Intervention: Legal use of benzodiazepines before admission
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Illegal use of benzodiazepines before admission
Number of subjects: 227

Group type: COMPARATOR
Intervention: No use of benzodiazepines before admission
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Benzodiazepines as adjuvant therapy
Number of subjects: 227
Study: 20961630

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived stem cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20961818

Group type: EXPERIMENTAL
Intervention: AquADEKs® softgels daily for 12 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AquADEKs® softgels
Number of subjects: 14
Study: 20961907

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (specifics not provided)
Number of subjects: 346

Group type: COMPARATOR
Intervention: CMV prophylaxis
Number of subjects: 346

Group type: COMPARATOR
Intervention: Antilymphocyte antibody administration
Number of subjects: 346
Study: 20962148

Group type: EXPERIMENTAL
Intervention: 25 μg/d cholecalciferol supplementation for 4 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Controlled intake providing 5 μg vitamin D and 1117 mg Ca/d
Number of subjects: 11
Study: 20962157

Group type: EXPERIMENTAL
Intervention: High dietary carbohydrate intake
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: High dietary total sugar intake
Number of subjects: 153

Group type: COMPARATOR
Intervention: Dietary variables
Number of subjects: 153
Study: 20964499

Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Moclobemide (300 mg/day)
Number of subjects: 53
Study: 20965184

Group type: EXPERIMENTAL
Intervention: Idiopathic gastroparesis (IG) patients with severe delay in gastric emptying (>35% retention at 4 hours)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Women with idiopathic gastroparesis
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Patients with acute-onset IG
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Overweight patients with IG
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Patients with severe delay in gastric emptying
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Patients with IG
Number of subjects: 243
Study: 20965491

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal prolapse repair using partially absorbable mesh
Number of subjects: 127
Study: 20965785

Group type: EXPERIMENTAL
Intervention: Imatinib discontinuation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imatinib reintroduction after relapse
Number of subjects: 100
Study: 20966039

Group type: EXPERIMENTAL
Intervention: Oxygen treatment for symptomatic familial pulmonary fibrosis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Asymptomatic observation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-resolution CT scan, pulmonary function tests, BAL analysis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Genetic sequencing and analyses
Number of subjects: 2
Study: 20967254

Group type: EXPERIMENTAL
Intervention: Screening based on presence of additional cardiovascular risk factors (n=431)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Screening for presence of albuminuria first (n=238)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Overall screening for albuminuria in apparently healthy population
Number of subjects: 1191
Study: 20967484

Group type: EXPERIMENTAL
Intervention: UCN-01 at 90 mg/m² over 3 h on cycle 1, reduced to 45 mg/m² over 3 h for subsequent cycles, every 21 days
Number of subjects: 17
Study: 20974302

Group type: EXPERIMENTAL
Intervention: dTpa (Boostrix™, GlaxoSmithKline Biologicals)
Number of subjects: 164
Study: 20976246

Group type: EXPERIMENTAL
Intervention: RareCover algorithm applied to re-sequencing data from FAAH and MGLL genes.
Number of subjects: 289

Group type: COMPARATOR
Intervention: RareCover algorithm
Number of subjects: 289
Study: 20976536

Group type: EXPERIMENTAL
Intervention: Overweight women
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 704
Study: 20977712

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Exclusive replacement feeding (ERF)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Antenatal education
Number of subjects: 81
Study: 20977716

Group type: EXPERIMENTAL
Intervention: Peer support intervention for exclusive infant feeding
Number of subjects: 0
Study: 20977715

Group type: EXPERIMENTAL
Intervention: Individual peer counselling (5 visits: before childbirth and during weeks 1, 4, 7, and 10 after childbirth)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Individual peer counselling (5 visits)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Individual peer counselling
Number of subjects: 370
Study: 20978227

Group type: EXPERIMENTAL
Intervention: Video-based coping skills (VCS) training with telephone coaching
Number of subjects: 116

Group type: COMPARATOR
Intervention: Wait List control condition
Number of subjects: 116
Study: 20978276

Group type: EXPERIMENTAL
Intervention: Marqibo (vincristine sulfate liposome injection, VSLI)
Number of subjects: 0
Study: 20979469

Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066) at a dose of 250 mg twice daily in 28-day cycles
Number of subjects: 82
Study: 20979472

Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066, Pfizer)
Number of subjects: 1

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1
Study: 20980172

Group type: EXPERIMENTAL
Intervention: Bovine thrombin product exposure (historical surgical procedure)
Number of subjects: 204
Study: 20980487

Group type: EXPERIMENTAL
Intervention: Higher saturated fatty acid consumption
Number of subjects: 137486

Group type: EXPERIMENTAL
Intervention: Higher monounsaturated fatty acid intake
Number of subjects: 137486

Group type: EXPERIMENTAL
Intervention: Higher polyunsaturated fatty acid intake
Number of subjects: 137486

Group type: EXPERIMENTAL
Intervention: Higher consumption of marine n-3 fatty acids
Number of subjects: 137486

Group type: EXPERIMENTAL
Intervention: Higher n-6 fatty acid intake
Number of subjects: 137486
Study: 20980658

Group type: EXPERIMENTAL
Intervention: Animal-based heme meal (intrinsically labeled (58)Fe pork)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ferrous sulfate ((57)Fe)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonheme iron
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heme iron
Number of subjects: 29
Study: 20980795

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA)
Number of subjects: 100
Study: 20980933

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine (PHiD-CV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7vCRM
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPw-HBV/Hib and poliovirus vaccines
Number of subjects: 0
Study: 20981430

Group type: EXPERIMENTAL
Intervention: GUCH patients
Number of subjects: 104
Study: 20981545

Group type: EXPERIMENTAL
Intervention: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine (1,000 mg/m2 on days 1, 8, and 15 every 28 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine
Number of subjects: 33
Study: 21028955

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 2500
Study: 21030409

Group type: EXPERIMENTAL
Intervention: Chronic vagus nerve stimulation (VNS) with CardioFit implantable system
Number of subjects: 32
Study: 21030492

Group type: EXPERIMENTAL
Intervention: Water-pipe smoking (WPS) for 30 minutes
Number of subjects: 45
Study: 21030496

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) and fotemustine (100 mg/m² on days 1, 8, and 15, repeated after 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fotemustine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fotemustine (in vitro)
Number of subjects: 20
Study: 21030558

Group type: EXPERIMENTAL
Intervention: Ex vivo anti-CD3/anti-CD28 costimulated autologous T cells + pneumococcal conjugate vaccine + multipeptide tumor antigen vaccine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pneumococcal conjugate vaccine only
Number of subjects: 54
Study: 21030579

Group type: EXPERIMENTAL
Intervention: Upper tertile of GFR (GFR>4.13 ml/min per 1.73 m2)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Anuric patients (urinary output<100 ml/24 h)
Number of subjects: 552
Study: 21030700

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg alteplase
Number of subjects: 57
Study: 21030717

Group type: EXPERIMENTAL
Intervention: Intrapericardial fat (IPF)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Extrapericardial fat (EPF)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hyperemic myocardial blood flow (MBF)
Number of subjects: 107
Study: 21034418

Group type: EXPERIMENTAL
Intervention: c-SN6j (chimeric anti-ENG monoclonal antibody)
Number of subjects: 0
Study: 21034448

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (healthy smokers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy nonsmokers
Number of subjects: 0
Study: 21034899

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 21035177

Group type: EXPERIMENTAL
Intervention: Frequent peanut consumption during pregnancy
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Frequent peanut consumption during pregnancy among infants never breast-fed
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: IgE levels to milk
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: IgE levels to egg
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 503
Study: 21035624

Group type: EXPERIMENTAL
Intervention: Armodafinil 100 mg PO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg PO
Number of subjects: 12
Study: 21035955

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg daily with SRS
Number of subjects: 10
Study: 21037128

Group type: EXPERIMENTAL
Intervention: DSM-IV criteria
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: ICD-10 criteria
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: MDAS cutoff score of 10
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Delirium Index cutoff score of 7
Number of subjects: 563
Study: 21037129

Group type: EXPERIMENTAL
Intervention: Low SAA (mean=2.4 [SD=0.9], n=23)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High SAA (mean=5.1 [SD=2.4], n=7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (low and high SAA)
Number of subjects: 30
Study: 21037195

Group type: EXPERIMENTAL
Intervention: 5 milligrams of zoledronic acid (ZOL) once yearly
Number of subjects: 5903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5903
Study: 21037442

Group type: EXPERIMENTAL
Intervention: Laparoscopic sphincter augmentation device (LINX Reflux Management System)
Number of subjects: 44
Study: 21039676

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Colonoscopy (gold standard)
Number of subjects: 545
Study: 21040519

Group type: EXPERIMENTAL
Intervention: VP shunt using the height/weight-based valve pressure-setting scheme
Number of subjects: 100
Study: 21041183

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg i.v. every 2 weeks) plus Erlotinib (150 mg/d orally)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biomarker analysis of tumor cell VEGF-A expression
Number of subjects: 40
Study: 21041705

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 10 mg/d intravenously for 10 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 32
Study: 21042071

Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment for male pattern baldness
Number of subjects: 0
Study: 21042103

Group type: EXPERIMENTAL
Intervention: Indocyanine green 4 mg per injection
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indocyanine green 6 mg per injection
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indocyanine green 2 mg per injection
Number of subjects: 6
Study: 21044339

Group type: EXPERIMENTAL
Intervention: Divalproex + Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divalproex + Placebo
Number of subjects: 0
Study: 21045179

Group type: EXPERIMENTAL
Intervention: Gamma imaging (740-mBq technetium 99m sestamibi injection)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Both gamma imaging and mammography combined
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Gamma imaging
Number of subjects: 1007
Study: 21047224

Group type: EXPERIMENTAL
Intervention: Everolimus (3.0 mg/m² orally)
Number of subjects: 28
Study: 21047225

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35) at a dose of 0.1 to 3.6 mg per kilogram of body weight every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)
Number of subjects: 45
Study: 21047927

Group type: EXPERIMENTAL
Intervention: High-calorie diet, relative physical inactivity, and administration of prednisolone (37.5 mg/d) for 12 days
Number of subjects: 10
Study: 21048059

Group type: EXPERIMENTAL
Intervention: Eating with mothers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Eating with friends
Number of subjects: 50
Study: 21048060

Group type: EXPERIMENTAL
Intervention: Protein restriction with medical food (n = 17 of 29)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Protein restriction with medical food and supplemental isoleucine or valine (n = 5 of 29)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Natural protein alone for dietary needs (n = 7 of 29)
Number of subjects: 29
Study: 21051557

Group type: EXPERIMENTAL
Intervention: High-dose lenalidomide (50 mg daily for up to 2 cycles)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-dose lenalidomide (10 mg daily after HD lenalidomide)
Number of subjects: 33
Study: 21051706

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.05 mL) treatment
Number of subjects: 30
Study: 21054208

Group type: COMPARATOR
Intervention: Ala/Ala group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Thr/Thr group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: TRH-stimulated TSH and free T4 levels
Number of subjects: 83
Study: 21054764

Group type: EXPERIMENTAL
Intervention: Screened group (5386 women)
Number of subjects: 8281

Group type: COMPARATOR
Intervention: Unscreened group (2895 women)
Number of subjects: 8281

Group type: EXPERIMENTAL
Intervention: Cytological AGC diagnosis
Number of subjects: 8281

Group type: EXPERIMENTAL
Intervention: Age ≥60 years
Number of subjects: 8281

Group type: EXPERIMENTAL
Intervention: Previous screening status
Number of subjects: 8281
Study: 21055747

Group type: EXPERIMENTAL
Intervention: Quinagolide (25-75 μg/d) administered for 18-20 weeks after L1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinagolide (25-75 μg/d)
Number of subjects: 9
Study: 21057003

Group type: COMPARATOR
Intervention: MMP-9 knockout mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human macrophage mRNA isolated from subjects with emphysema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating monocytes in individuals with advanced emphysema severity
Number of subjects: 0
Study: 21057794

Group type: EXPERIMENTAL
Intervention: Safety-engineered devices (mechanical aspirating syringe, antineedlestick safety needle)
Number of subjects: 110
Study: 21059176

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg on demand (1-3 hours before intercourse) for 12 or 24 weeks
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg on demand (1-3 hours before intercourse) for 12 or 24 weeks
Number of subjects: 6081

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg daily (included in safety assessments only) or on demand for 9 weeks
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: Dapoxetine (both doses)
Number of subjects: 6081
Study: 21059672

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day s.c.) and MTX
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Gene profiling
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IL-1β associated genes
Number of subjects: 32
Study: 21060028

Group type: EXPERIMENTAL
Intervention: Cediranib at 12 mg/m(2)/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cediranib at 8 mg/m(2)/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cediranib at 17 mg/m(2)/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 16
Study: 21060320

Group type: EXPERIMENTAL
Intervention: T cell manipulation for asthma therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: T(H)2 cytokines (IL-4, IL-5, IL-13)
Number of subjects: 0
Study: 21062137

Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan/HCT (12.5 or 25 mg)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan with or without HCT
Number of subjects: 601
Study: 21062428

Group type: EXPERIMENTAL
Intervention: Carbon ion boost in conjunction with photon radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard photon treatment
Number of subjects: 0
Study: 21062463

Group type: EXPERIMENTAL
Intervention: Locking compression 2.4 mm plates for distal radius fractures
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Proximal humerus internal locking plates for proximal humerus fractures
Number of subjects: 2

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2
Study: 21069335

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) and Docetaxel (75 mg/m(2))
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pemetrexed and Docetaxel (escalating doses)
Number of subjects: 62
Study: 21070142

Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg/day for 7 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg/day for 7 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Artesunate 2 mg/kg/day for 7 days
Number of subjects: 26
Study: 21070531

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0
Study: 21070978

Group type: EXPERIMENTAL
Intervention: Nutrition counseling via telemedicine
Number of subjects: 74
Study: 21071497

Group type: EXPERIMENTAL
Intervention: Deferasirox therapy (mean dose 36.1 ± 7.7 mg/kg/d during the second year)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Deferasirox therapy
Number of subjects: 101
Study: 21071723

Group type: EXPERIMENTAL
Intervention: Alteplase (tissue plasminogen activator [tPA])
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Standardized weighing before thrombolysis
Number of subjects: 109
Study: 21071966

Group type: EXPERIMENTAL
Intervention: Dialyzer designed for increased internal filtration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control dialyzer
Number of subjects: 12
Study: 21072184

Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 35
Study: 21072603

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (marathon running)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (inactive individuals)
Number of subjects: 114
Study: 21073392

Group type: EXPERIMENTAL
Intervention: Lansoprazole (median dose 90 mg/day)
Number of subjects: 21
Study: 21074011

Group type: EXPERIMENTAL
Intervention: Continuous LNG 90 mcg/EE 20 mcg
Number of subjects: 79
Study: 21075272

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules (MS-sNT)
Number of subjects: 465
Study: 21078419

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens with anthracyclines or anthracycline/taxane combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MFI-20 (Multidimensional Fatigue Inventory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (European Organization for Research and Treatment Quality of Life Questionnaire)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LOR (Life Orientation Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAI (State-Trait Anxiety Questionnaire)
Number of subjects: 0
Study: 21078684

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal-weight subjects with normal glucose tolerance (NGT)
Number of subjects: 119